Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1epositive metastatic colorectal cancer (mCRC)-MedSci.cn

Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1epositive metastatic colorectal cancer (mCRC)

Kim, T; Taieb, J; Passhak, M; Kim, T; Kim, S; Geva, R; Hofsli, E; Perl, G; Yalcin, S; Hubert, A; Somer, B; Wong, Z; Wang, A; Leconte, P; Fogelman, D; Heinemann, V

ANNALS OF ONCOLOGY, 2022; 33 (): S277

科室
- - 订阅+
  - 更多科室
工具
服务